CSIMarket Company Name, Ticker, Customers, else..
 
Trevi Therapeutics Inc   (TRVI)
Other Ticker:  
 
 
Price: $3.5100 $0.14 4.154%
Day's High: $3.68 Week Perf: 11.43 %
Day's Low: $ 3.38 30 Day Perf: 27.64 %
Volume (M): 720 52 Wk High: $ 4.00
Volume (M$): $ 2,528 52 Wk Avg: $2.32
Open: $3.42 52 Wk Low: $0.97



 Market Capitalization (Millions $) 349
 Shares Outstanding (Millions) 99
 Employees 30
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -27
 Cash Flow (TTM) (Millions $) -41
 Capital Exp. (TTM) (Millions $) 0

Trevi Therapeutics Inc
Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company that primarily focuses on developing and commercializing drugs for neurological disorders. The company was founded in 2011 and is headquartered in New Haven, Connecticut.

The company's lead product candidate is nalbuphine ER, which is a novel extended-release formulation of nalbuphine, an opioid-based drug. It is under development for the treatment of several severe neurological conditions, including pruritus (severe itching) associated with conditions such as chronic liver disease and uremic (kidney-related) pruritus.

Trevi's pipeline also includes other drug candidates. One of them is TRV027, which is a novel human angiotensin type II receptor (AT2R) agonist. It is under development for the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), which are severe and often fatal conditions that affect the lungs.

The company's scientific approach is based on in-depth understanding of the underlying pathophysiology of the diseases it targets. It uses innovative drug delivery technologies to extend the half-life of its drug candidates and optimize their therapeutic potential.

Trevi has partnerships with several leading institutions in the field of neurological research, including the National Institute of Neurological Disorders and Stroke, the National Institute on Aging, and the Michael J. Fox Foundation for Parkinson's Research. The company is also engaged in collaborations with academic institutions and other pharmaceutical companies to advance the understanding of neurological diseases and develop innovative therapies.

In addition, Trevi has a strong management team with extensive experience in drug development and commercialization. Its executives have a track record of successfully bringing innovative therapies to market.

Overall, Trevi Therapeutics Inc. is a promising biopharmaceutical company that is dedicated to developing innovative therapies for severe neurological disorders. With its strong scientific approach, innovative drug delivery technologies, and experienced management team, it has the potential to create significant value for patients and investors alike.


   Company Address: 195 Church Street New Haven 6510 CT
   Company Phone Number: 304-2499   Stock Exchange / Ticker: NASDAQ TRVI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Trevi Therapeutics Inc

Trevi Therapeutics Inc: Operating Deficit Narrows, Progress Towards Financial Stability

Trevi Therapeutics Inc: A Look into the Company's Financial Performance and Future Prospects
Investors eagerly awaited the earnings cycle of fiscal July to September 30, 2023, at Trevi Therapeutics Inc (TRVI), hoping for positive news that could boost their confidence in the company. However, the company reported an operating deficit of $-9.045 million during that period, causing some concern among stockholders. It is worth noting, though, that this deficit has actually contracted from the previous quarter's figure of $-8.405 million, suggesting progress in the right direction.
One question on everyone's minds is when the company will start reporting revenue. Market observers have been speculating about this crucial milestone for Trevi Therapeutics Inc. While the anticipation grows, the management has been hard at work to make the company more cost-effective, leading to a reduction in the deficit. As of September 30, 2023, the deficit stands at $-7.698 million, indicating that management is making strides toward financial stability.
Trevi Therapeutics Inc

TRVI Surpasses Expectations with Strong Second Quarter Results for 2023

Trevi Therapeutics Inc is a pharmaceutical company that specializes in major pharmaceutical preparations. As advisors in the sector interpret the second quarter results of 2023, they have noticed a significant operating shortfall of $-8.382 million. Surprisingly, the company has not yet cited any revenue for the respective April to June quarter, leaving investors guessing when the revenue will begin to show.
Comparing the figures to the second quarter of 2022, there has been a contraction in the operating shortfall from $-7.82 million. This contraction signifies some improvement, but the lack of revenue remains a concern for investors. With the company still in the early stages of developing its business model, it is commendable that they have managed to save $-7.145 million in the April to June 2023 timeframe, compared to $-8.052 million in the second quarter of 2022.
Trevi Therapeutics Inc

1) Trevi Therapeutics Inc Posts Huge Operating Loss of $-7.563 Million for Q1 2023

Trevi Therapeutics Inc is a pharmaceutical company that specializes in developing therapeutics for neurological disorders. The company?s primary focus is on developing a drug called Nalbuphine ER, which aims to provide pain relief for people with chronic severe pruritus or severe itching. Trevi Therapeutics Inc is based in New Haven, Connecticut and was founded in 2011.
As the January to March 31 2023 reporting season has continued, many companies have announced their financial results, and Trevi Therapeutics Inc is among them. The company reported an operating loss of $-7.563 million for the financial time-frame closing on March 31, 2023. This is a decline from their operating loss of $-7.025 million in the first quarter of 2022.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com